Hillevax Inc
HLVX2.060USD
+0.020+0.98%
交易中 （美东）报价延迟15分钟
103.21M总市值
亏损市盈率 TTM
关于 Hillevax Inc 公司
HilleVax, Inc. 是一家临床阶段的生物制药公司，专注于疫苗的开发和商业化。该公司的 HIL-214 项目是一种基于病毒样颗粒 (VLP) 的候选疫苗，用于预防诺如病毒感染引起的中度至重度急性胃肠炎 (AGE)。诺如病毒是全球最常见的病毒性 AGE 病因，其症状包括腹泻、呕吐、腹痛、恶心，有时还会出现发烧，可能导致临床上严重的脱水。该公司的 HIL-214 是一种二价（含有两种蛋白质）候选疫苗，由代表两种常见诺如病毒基因型的 VLP 组成，并与氢氧化铝 (alum) 佐剂共同配制，后者常用于成人和儿童疫苗中以增强免疫原性。 HIL-216 包括六种常见的诺如病毒基因型，GI.1、GII.2、GII.3、GII.4、GII.6 和 GII.17。
公司简介
公司代码HLVX
公司名称Hillevax Inc
上市日期Apr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
员工数量14
证券类型Ordinary Share
年结日Apr 29
公司地址321 Harrison Ave, Suite 500
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02118
电话16172135054
网址https://www.hillevax.com/
公司代码HLVX
上市日期Apr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Dr. Nanette Cocero, Ph.D.
Dr. Nanette Cocero, Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Aditya Kohli, Ph.D.
Dr. Aditya Kohli, Ph.D.
Director
Director
--
--
Dr. Julie Louise Gerberding, M.D.
Dr. Julie Louise Gerberding, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月29日 周二
更新时间: 7月29日 周二
持股股东
股东类型
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
股东类型
持股股东
占比
Private Equity
22.82%
Hedge Fund
16.80%
Investment Advisor/Hedge Fund
15.22%
Corporation
13.41%
Investment Advisor
11.56%
Venture Capital
9.11%
Individual Investor
3.71%
Research Firm
1.02%
Bank and Trust
0.08%
Other
6.27%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
224
44.13M
88.00%
-14.24M
2025Q1
229
46.31M
92.39%
-14.77M
2024Q4
226
47.12M
94.62%
-13.67M
2024Q3
218
46.00M
92.53%
-13.52M
2024Q2
202
49.77M
100.23%
-2.02M
2024Q1
182
48.47M
97.79%
-558.66K
2023Q4
166
46.57M
96.99%
+4.81M
2023Q3
161
39.77M
86.30%
+8.72M
2023Q2
146
30.99M
80.52%
+1.24M
2023Q1
140
32.25M
85.25%
+3.76M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
10.62M
21.17%
--
--
Mar 31, 2025
Takeda Pharmaceutical Co Ltd
6.72M
13.41%
--
--
Mar 31, 2025
Tang Capital Management, LLC
4.92M
9.81%
--
--
May 02, 2025
Lightspeed Venture Partners
2.30M
4.59%
-37.51K
-1.60%
Mar 31, 2025
Franklin Advisers, Inc.
1.95M
3.9%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
3.82%
-70.63K
-3.56%
Mar 31, 2025
Deerfield Management Company, L.P.
1.88M
3.75%
--
--
Mar 31, 2025
Abingworth Management Limited
1.84M
3.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.59M
3.16%
-20.50K
-1.28%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Global X Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
Global X Russell 2000 ETF
占比0%
Avantis Responsible US Equity ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
